• Publications
  • Influence
Risk factors for doxorubicin-induced congestive heart failure.
There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule. Expand
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Liposomal doxorubicin has substantial activity against ovarian cancer refractory to platinum and paclitaxel and this liposomal formulation should be evaluated further in combination with other drugs in lessRefractory patients. Expand
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Age, PS, tumor histology, and residual tumor volume were independent predictors of prognosis in patients with stage III EOC and can be used to identify patients with poor prognosis and to design future tailored randomized clinical trials. Expand
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
Cisplatin alone or in combination yielded superior response rates and PFS relative to paclitaxel; however, OS was similar in all three arms, and the combination therapy had a better toxicity profile; therefore, the combination of cisplatin and pac litaxel remains the preferred initial treatment option. Expand
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer. Expand
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
The role of complement activation in hypersensitivity reactions associated with administration of paclitaxel in Cremophor EL plus ethanol should be studied in vivo. Expand
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
The toxicity profile of DOX-SL differs prominently from that of the free drug administered by bolus or rapid infusion and with some differences, resembles that of prolonged continuous infusion. Expand
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.
C activation may play a key role in HSRs to Doxil, however, low-level C activation does not necessarily entail clinical symptoms, highlighting the probable involvement of further, as yet unidentified, amplification factors. Expand
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
Daunomycin, like its anthracycline analog adriamycin, is a cardiotoxic antitumor antibiotic and dose-response curves constructed enable the clinician to judge the relative risk of developing cardiomyopathy at a given total dosage level and allows comparison of the human experience with the experimental animal model data. Expand
The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial
The authorship of the report "The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma: A Randomized Phase III Trial," published in the October 1989 issue (J Clin OncolExpand